Obesity also increases cardiovascular and respiratory morbidities, which are coupled to increased ICU demand and deaths among infected cases.Video abstract http//links.lww.com/CAEN/A25.
 This article shows a tight correlation between average BMI, food supply per country, and COVID-19-related deaths. Such predisposing factors might operate by upregulating the inflammation pathway in heavily struck countries, leading to easier triggering of the infamous cytokine storm syndrome. Obesity also increases cardiovascular and respiratory morbidities, which are coupled to increased ICU demand and deaths among infected cases.Video abstract http//links.lww.com/CAEN/A25.Type 2 diabetes mellitus is not just a risk factor but a progression factor for a plethora of multi-organ complications, including the liver and the vascular system. The profibrogenic-inflammatory liver disease nonalcoholic steatohepatitis affects patient's mortality and overall cardiovascular and liver-related complications.  https://www.selleckchem.com/products/VX-770.html  There is an evident overlap between these diseases; therefore, there are important implications for endocrinologists, cardiologists, and hepatologists when treating these patients. In addition, as newly approved nonalcoholic steatohepatitis pharmacotherapy is expected to be available early this year, clinicians need to be able to identify patients with type 2 diabetes mellitus that are at risk of advanced liver fibrosis to establish adequate and efficient management plans to limit or avoid cardiovascular or liver-related complications. In this review, we summarize the current knowledge in the nonalcoholic steatohepatitis field with potential value for clinicians focusing on the implications of the overlap between type 2 diabetes mellitus, cardiovascular disease, and nonalcoholic steatohepatitis, the available diagnostic tools for risk stratification, management pathways, and nonalcoholic steatohepatitis pharmacotherapy, including antidiabetic and cardiovascular drugs that may be beneficial or detrimental to their patients.Ageing is associated with chronic inflammation and oxidative stress that increase the risk of cardiovascular disease. Frailty and sarcopenia, which are associated with increased visceral obesity and muscle mass loss, are now emerging as new potential risk factors for cardiovascular disease. Increased muscle visceral fat leads to increased secretion of harmful proinflammatory adipokines and reduced muscle mass leads to reduced secretion of the protective myokines creating an abnormal cardiometabolic state increasing the risk of cardiovascular disease. This review (1) explore traditional and newly emerging cardiometabolic risk factors in older people; (2) investigate methods of prediction and prevention of cardiovascular disease in those with diabetes; and (3) concludes that the development of a subspeciality of Cardiometabolic Medicine should be considered.More than 100 million people in the USA have diabetes or prediabetes and are at high risk for developing cardiovascular disease. Current evidence-based guidelines support a multifactorial approach in patients with diabetes, including lifestyle intervention and pharmacological treatment of hyperglycemia, hypertension, and dyslipidemia. In addition, recent cardiovascular outcome trials demonstrated that sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists improve cardiovascular outcomes in patients with diabetes. Albeit this evidence, over 80% of patients with diabetes do not achieve the recommended treatment goals. Considering the rising burden of cardiovascular complications, there is need to improve the quality of care in patients with diabetes. In this review, we discuss the current quality of health care in patients with diabetes in the USA, identify barriers to achieve guideline-recommended treatment goals and outline opportunities for the improvement in caring for patients with diabetes.The high prevalence of cardiovascular disease and worldwide diabetes epidemic has created an ever-increasing burden on the healthcare system. This calls for the creation of a new medicine subspecialty cardiometabolic medicine. Using information from review articles listed on PubMed and professional society guidelines, the authors advocate for a cardiometabolic medicine specialization training program. The curriculum would integrate relevant knowledge and skills of cardiology and endocrinology as well as content of other disciplines essential to the optimal care of cardiometabolic patients, such as epidemiology, biostatistics, behavioral science and psychology. Cardiometabolic medicine should be seen as an opportunity for life-long learning, with core concepts introduced in medical school and continuing through CME courses for practicing physicians. To improve care for complex patients with multiple co-morbidities, a paradigm shift must occur, transforming siloed education, and treatment and training to interdisciplinary and collaborative work.The increasing societal demand for data privacy has led researchers to develop methods to preserve privacy in data analysis. However, outlier analysis, a fundamental data analytics task with critical applications in medicine, finance, and national security, has only been analyzed for a few specialized cases of data privacy. This work is the first to provide a general framework for private outlier analysis, which is a two-step process. First, we show how to identify the relevant problem-specifications and then provide a practical solution that formally meets these specifications.In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. We followed the current recommendations by the American Society of Hematology, which have been modified accordingly to fit the specific realities associated with the management of WM. In this Consensus Statement, the Panel addresses questions related to treatment initiation, preferred therapies, minimizing visit to clinics and infusions centers, supportive care and guidance for WM patients in clinical trials. Finally, we also provide information on timing and appropriateness of testing and management of COVID-19 infected patients, as well as ways to get physicians and patients involved in registry studies that could help others.